## 

## **Complex Biotech Co., Ltd**

## **CD317 Recombinant Protein**

Catalog:	BCP3486	Host:	E.coli		Tag:	His-tag	
BackGrou	ınd:			Swiss-l	Prot:		
BST2 (CD	317, Tetherin, HM1.24	4) is a type	II transmem-	Q1058	89		
brane glyco	oprotein functioning as	s a major me	ediator of the	Purific	ation&Pur	ity:	
innate immune defense against the dissemination of en-			Transfe	Transferred into competent cells and the super			
veloped vir	ruses by tethering virc	on on cell su	urface. BST2	purified	by NI colu	ımn affinity chr	omatograp
has a N-ter	minal cytoplasmic tai	l for entocy	tosis and cy-	purity is	s > 85% (by	SDS-PAGE).	
toskelatal s	signaling, a transmem	brane doma	in, an extra-	Restric	ction Sites:		
cellular do	main containing putat	tive disulfid	le bonds and	NdeI-X	hoI		
coiled coi	l region for formin	ng homodi	mer, and a	Storag	e&Stability	7 <b>•</b>	
C-terminal	GPI domain for mem	bran anchor	ing. Both the	Store at	±4℃ short t	term. Aliquot an	d store at
	rane domain and the			term. A	void freeze-t	haw cycles.	
	ne cell membrane or t		-	Expres	sion Vector	••	
	hold them together to			pet-22b	(+)		

**DATA:** 

258	-
95	-
65	
52	
41	
33	
25	
17	
10	

Note:

For research use only, not for use in diagnostic procedure.

rus counteracts BST2 by encoding viral protein as antagonist. These viral proteins interact directly with BST2 to either enhance BST2 endocytosis/lysosomal degradation (such as Vpu) or prevent BST2 secretion pathway by sequestering the protein in endosome. BST2 is overexpressed in gastrointestinal cancers, breast cancer, lung cancer and multiple myeloma. BST2 monoclonal antibody targeting myeloma or lung cancer cells induces celllular cytotoxicity and cell death (ADCC, antibody-dependent cell-mediated cytotoxicity). Thus BST2 serves as a potential target for tumor immunotherapy.

**Product:** 

PBS, 4M Urea, PH7.4

**Molecular Weight:** 

~16kDa

ernatant was phy and the

-20 ℃ long